VCNX

27.38% -0.1944

Dopo l'orario di chiusura: .52 0.00442 +0.86%

Vaccinex Inc (VCNX)

Panoramica Notizia Cronologia dei prezzi Financials Perché VCNX Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

Volume 24 ore:

Relative Volume:

Capitalizzazione di mercato:

Utile/perdita netta:

Rapporto P/E:

Flusso di cassa netto:

1 W Prestazione:

1M Prestazione:

6M Prestazione:

1 anno Prestazione:

Intervallo 1D:

Intervallo di 1 settimana:

Portata 52W:

Vaccinex Inc Stock (VCNX) Company Profile

Vaccinex Inc

Healthcare (1159)

Biotechnology (645)

Prossima data di guadagno

Ultimi documenti SEC

VCNX's Discussions on Twitter

Confronta VCNX con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
VCNX Vaccinex Inc	0.5156	0	0	-22.01M	-18.31M	-85.40
VRTX Vertex Pharmaceuticals Inc	397.46	99.96B	11.39B	3.64B	3.50B	13.99
REGN Regeneron Pharmaceuticals Inc	598.16	60.83B	14.21B	4.46B	3.56B	39.68
ALNY Alnylam Pharmaceuticals Inc	467.55	59.89B	2.46B	-319.09M	-52.09M	-2.47
ARGX Argen X Se Adr	663.73	40.47B	3.06B	1.28B	447.35M	21.30
ONC Beone Medicines Ltd Adr	313.97	37.96B	3.81B	-644.79M	-669.77M	-6.24

Vaccinex Inc Stock (VCNX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2020-09-23	Downgrade	BTIG Research	Buy → Neutral
2018-09-04	Iniziato	Ladenburg Thalmann	Buy

Vaccinex Inc Borsa (VCNX) Ultime notizie

Vaccinex Inc Azioni (VCNX) Dati Finanziari

Vaccinex Inc (VCNX)

Vaccinex Inc Stock (VCNX) Company Profile

Confronta VCNX con altri titoli

Vaccinex Inc Stock (VCNX) Upgrades & Downgrades

Vaccinex Inc Borsa (VCNX) Ultime notizie

Vaccinex (NASDAQ:VCNX) Trading 26.3% Higher – Here’s Why - Defense World

Cannabinoid Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - India Shorts

Progressive Supranuclear Palsy Market on Upward Trajectory During the Forecast Period (2025-2034) with Emerging Immunotherapies | DelveInsight - The Malaysian Reserve

Huntington’s Disease Market to Expand Significantly by 2034, States DelveInsight Report | Prilenia Therapeutics, Neurocrine Biosciences, Som Biotech, Annexon Biosciences, Vaccinex, Sage Therapeutics - Barchart.com

Huntington's Disease Market To Expand Significantly By 2034, States Delveinsight Report Prilenia Therapeutics, Neurocrine Biosciences, Som Biotech, Annexon Biosciences, Vaccinex, Sage Therapeutics - Menafn

Best Biotech Penny Stocks Right Now • Updated Daily - Benzinga

Cannabinoid Agonist Clinical Trial Pipeline Appears Robust - GlobeNewswire

Alzheimer’s Therapeutics Market on Upward Trajectory Across - GlobeNewswire

Vaccinex (NASDAQ:VCNX) Shares Down 2.7% – Time to Sell? - Defense World

Alzheimer's Disease Clinical Trials 2025: EMA, PDMA, FDA - openPR.com

Vaccinex (NASDAQ:VCNX) Shares Down 2.4% – Time to Sell? - Defense World

Vaccinex presents promising cancer treatment data at ASCO By Investing.com - Investing.com India

Vaccinex to Report Promising New Clinical Results of Neoadjuvant - GuruFocus

Vaccinex presents promising cancer treatment data at ASCO - Investing.com

Vaccinex, Inc. to Present New Data on Pepinemab's Role in Enhancing Immune Responses in Head and Neck Cancer at ASCO 2025 - Nasdaq

Vaccinex to Report Promising New Clinical Results of - GlobeNewswire

Clinical Trial Success: New Drug Transforms Cold Tumors into Hot Immune Centers in Head and Neck Cancer - Stock Titan

Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting - GlobeNewswire

Vaccinex (NASDAQ:VCNX) Stock Price Down 11.3% – Here’s What Happened - Defense World

AbTherx, Single Cell Technology, and Vaccinex Announce Collaboration to Tackle Challenging Antibody Drug Targets - ACCESS Newswire

Vaccinex (NASDAQ:VCNX) Trading 9.9% Higher – Still a Buy? - Defense World

Vaccinex reports pepinemab boosts immune response in cancer By Investing.com - Investing.com South Africa

Vaccinex (VCNX) Presents New Findings on Pepinemab for Cancer Tr - GuruFocus

Vaccinex to Report Promising New Clinical Data Revealing Pepinem - GuruFocus

Vaccinex to Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR) | VCNX Stock News - GuruFocus

Vaccinex to Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR) - The Manila Times

Vaccinex reports pepinemab boosts immune response in cancer - Investing.com Australia

Vaccinex, Inc. Announces Promising Data on Pepinemab as Neoadjuvant Immunotherapy in Metastatic Melanoma and Head and Neck Cancer at AACR 2025 - Nasdaq

Vaccinex to Report Promising New Clinical Data Revealing - GlobeNewswire

VACCINEX, INC. SEC 10-K Report - TradingView

Pre-market Movers In Healthcare Sector: CTXR, VCNX, SRNE, ITRM, RWLK… - RTTNews

Osteosarcoma Market Set for Groundbreaking Expansion by 2032, Forecasts DelveInsight | Aurora Biopharma, BioAtla, Iovance Biotherapeutics, Isofol Medical AB, Bristol-Myers Squibb, Cellestia Biotech - The Globe and Mail

Vaccinex Delays Yearly Report Filing - TipRanks

Vaccinex director resigns, no disagreement cited By Investing.com - Investing.com South Africa

Vaccinex director resigns, no disagreement cited - Investing.com India

Stocks in play: Neo Performance Materials Inc. - The Globe and Mail

Finance Watch: Sutro Halves Workforce, Cuts Lead ADC And CEO Moves On - Citeline News & Insights

Vaccinex plans Nasdaq exit as Alzheimer market pressure grows - Yahoo Finance

Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market - GlobeNewswire

Can Vaccinex Survive After Nasdaq Exit? Key Details on Company's Future Strategy - StockTitan

Vaccinex Stock Price, Quotes and Forecasts | OTC:VCNX - Benzinga

Vaccinex (NASDAQ:VCNX) Stock Price Down 3.7% – Time to Sell? - Defense World

Alzheimer's Disease Clinical Trial Pipeline | 110+ Companies Pioneering Breakthroughs in Treatment | - EIN News

RFK Jr. says he's resigned from anti-vaccine nonprofit as he seeks nation's top health official job - AP News

Louisiana forbids public health workers from promoting COVID, flu and mpox shots : ShotsHealth News - NPR

United States shares lower at close of trade; Dow Jones Industrial Average down 0.61% - Investing.com India

Vaccinex to be delisted from Nasdaq over equity shortfall - Investing.com

Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire

SIMM Launches WNY Stock Index - The Bona Venture

Vaccinex Inc (VCNX) Quarterly 10-Q Report - Quartz

75+ Key Companies Charting New Frontiers in Multiple Sclerosis Therapeutic Space | DelveInsight - Yahoo Finance

Vaccinex Inc Azioni (VCNX) Dati Finanziari

Reddito

Reddito netto

Flusso di cassa

EPS

Simile a VCNX